|Olamkicept is a recombinant protein that fuses the extracellular domain of the signal transducing subunit of the IL-6 receptor, IL-6Rβ (glycoprotein 130, gp130), to a human IgG Fc fragment . The full construct is a dimer of covalently linked identical peptide chains. Mechanistically olamkicept acts as an inhibitor of the IL-6 signalling pathway. Olamkicept inhibits trans signalling by the soluble IL-6 receptor (sIL-6R) , a mechanism that is involved in human inflammatory and autoimmune diseases . It is hypothesised to be clinically effective in reducing disease signs and symptoms whilst not being detrimental to the role of IL-6 in the acute immune response to infection.